Mental Health and Telemedicine Organizations and Their Events

A Worldwide Calendar and Locator Resource
Maintained by Myron Pulier, MD

This Page Runs From NB- to NEUZ-

• Behavioral sciences (psychology)
• Business communication
• Personnel and organization (or human resources management)

Nefesh:

• Provides international and regional leadership addressing mental health issues in the Orthodox community and Jewish community at large
• Conducts international, regional, and local training, and symposia
• Integrates clinical, spiritual, and religious practice

The Network Eating Disorders has set itself objectives ranging from using public relations to enhance public understanding of eating disorders through advising and motivation work for sufferers and their relatives to prevention and health promotion.

The Network Eating Disorders provides and interdisciplinary curriculum for specialization in treatment of eating disorders, internship positions and other training for profesisonals. It holds international conferences for sufferers, their relatives and experts in the field.

Objectives:

• Improve the psychosocial situation of sufferers and their relatives
• Break down individual and social prejudices against sufferers from Eating Disorders
• Enhance public understanding of eating disorders and identify those socio-cultural factors that may contribute to the onset of an eating disorder and to help to change these factors
• Achieve a more adequate treatment for sufferers
• Increase quantity and improve quality of treatment and of available self-help

Objectives:

• Map the potential for setting up an integrative model to address all scientific aspects of mental health (genetics, biomarkers, functional imaging, cognition and emotion, neurophysiology, pharmacological challenges in animal models as well as human volunteers)
• Foster and ensure a multidisciplinary approach in fundamental and basic research
• Provide mechanisms to speed up bench to the bedside research (from basic research to clinical research), and accelerate the time to market for products and services in the field of mental health applications (industrial applications in medicine, medical devices and ICT solutions)
• Gain better understanding of behavioural aspects of patients suffering from dementia
• Address the increasing societal burden of an aging population suffering from mental disorders (policy-making)

1. MAOIs Master Course and Mentorship New York, NY: June 9, 2012
2. Core Beliefs on Trial: "A Cognitive Therapy Approach for Psychopharmacologists" Carlsbad, CA: June 28-30, 2012
3. MAOIs Master Course and Mentorship Los Angeles, CA: July 14, 2012
4. MAOIs Master Course and Mentorship Los Angeles, CA: September 15, 2012
5. Global Psychopharmacology Congress San Diego, CA: October 18-21, 2012
6. Global Psychopharmacology Congress Colorado Springs, CO: November 14-17, 2013

The following unmet needs and professional practice gaps regarding depression were revealed following a critical analysis of activity feedback, expert faculty assessment, and literature review, as well as through new medical knowledge:

• The timely detection, diagnosis, and treatment of major depression have been shown to increase the probability of positive clinical outcomes; however, only 60% of those with depression are actually being treated
• Even when correctly diagnosed and treated, as many as two-thirds of MDD patients will not respond to the first antidepressant prescribed, and a substantial number may be treatment-resistant
• In a 2012 NEI Survey, only half of respondents felt competent prescribing an MAOI to patients with treatment-resistant depression

To help address clinician performance deficits with respect to diagnosis and treatment of depression, quality improvement efforts need to provide education regarding under-used evidence-based treatment strategies for patients with treatment-resistant depression.

Objectives:

• Explain the role of monoamine oxidase in the neurobiology, etiology, and presentation of psychiatric illnesses, including depression
• Identify foods and medications that interact with MAO inhibitors
• Implement safe management strategies when switching between MAO inhibitors and serotonin reuptake inhibitors
• Integrate MAO inhibitors into clinical practice according to best practices standards

Faculty:

• Stephen M Stahl, MD, PhD, Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine; Honorary Visiting Senior Fellow, University of Cambridge, UK
• Thomas L Schwartz, MD, Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York
• Michael J Gitlin, MD, Professor, Psychiatry and Biobehavioral Sciences, University of California, Los Angeles [UCLA] School of Medicine; Director, Adult Division and Director, Mood Disorders Clinic, UCLA Neuropsychiatric Hospital

Objectives:

• Explain the cognitive model to patients, using TBCT cognitive conceptualization diagram, so patients understand the relation between situation, thought, emotion and behavior/physical reaction
• Use intra-personal thought record so patients are confident implementing its use in session
• Improve patients' ambivalence toward the relevant topic using consensual role-play
• Use Trial I to reduce a patient's mean percentage of the negative core belief and emotion by at least 60%
• Use Trial II to teach patients the metacognitive character of their thoughts and beliefs
• Use responsibility grid with patients facing events that produce feelings of guilt

Trainers:

• Irismar Reis de Oliveira, MD, PhD, Professor of Psychiatry, Department of Neurosciences and Mental Health, Post-Graduation Program, Professor Edgar Santos University Hospital, Federal University of Bahia, Salvador, Brazil
• Donna Sudak, MD , Founding Fellow, Academy of Cognitive Therapy; President, Academy of Cognitive Therapy; Director, Psychotherapy Training; Professor of Psychiatry, Drexel University College of Medicine

The following unmet needs and professional practice gaps regarding depression were revealed following a critical analysis of activity feedback, expert faculty assessment, and literature review, as well as through new medical knowledge:

• The timely detection, diagnosis, and treatment of major depression have been shown to increase the probability of positive clinical outcomes; however, only 60% of those with depression are actually being treated
• Even when correctly diagnosed and treated, as many as two-thirds of MDD patients will not respond to the first antidepressant prescribed, and a substantial number may be treatment-resistant
• In a 2012 NEI Survey, only half of respondents felt competent prescribing an MAOI to patients with treatment-resistant depression

To help address clinician performance deficits with respect to diagnosis and treatment of depression, quality improvement efforts need to provide education regarding under-used evidence-based treatment strategies for patients with treatment-resistant depression.

Objectives:

• Explain the role of monoamine oxidase in the neurobiology, etiology, and presentation of psychiatric illnesses, including depression
• Identify foods and medications that interact with MAO inhibitors
• Implement safe management strategies when switching between MAO inhibitors and serotonin reuptake inhibitors
• Integrate MAO inhibitors into clinical practice according to best practices standards

Faculty:

• Stephen M Stahl, MD, PhD, Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine; Honorary Visiting Senior Fellow, University of Cambridge, UK
• Thomas L Schwartz, MD, Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York
• Michael J Gitlin, MD, Professor, Psychiatry and Biobehavioral Sciences, University of California, Los Angeles [UCLA] School of Medicine; Director, Adult Division and Director, Mood Disorders Clinic, UCLA Neuropsychiatric Hospital

The following unmet needs and professional practice gaps regarding depression were revealed following a critical analysis of activity feedback, expert faculty assessment, and literature review, as well as through new medical knowledge:

• The timely detection, diagnosis, and treatment of major depression have been shown to increase the probability of positive clinical outcomes; however, only 60% of those with depression are actually being treated
• Even when correctly diagnosed and treated, as many as two-thirds of MDD patients will not respond to the first antidepressant prescribed, and a substantial number may be treatment-resistant
• In a 2012 NEI Survey, only half of respondents felt competent prescribing an MAOI to patients with treatment-resistant depression

To help address clinician performance deficits with respect to diagnosis and treatment of depression, quality improvement efforts need to provide education regarding under-used evidence-based treatment strategies for patients with treatment-resistant depression.

Objectives:

• Explain the role of monoamine oxidase in the neurobiology, etiology, and presentation of psychiatric illnesses, including depression
• Identify foods and medications that interact with MAO inhibitors
• Implement safe management strategies when switching between MAO inhibitors and serotonin reuptake inhibitors
• Integrate MAO inhibitors into clinical practice according to best practices standards

Faculty:

• Stephen M Stahl, MD, PhD, Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine; Honorary Visiting Senior Fellow, University of Cambridge, UK
• Thomas L Schwartz, MD, Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York
• Michael J Gitlin, MD, Professor, Psychiatry and Biobehavioral Sciences, University of California, Los Angeles [UCLA] School of Medicine; Director, Adult Division and Director, Mood Disorders Clinic, UCLA Neuropsychiatric Hospital

Objectives:

• Reduce institutional barriers to schizophrenia research
• Provide a focal point for scientists and clinicians conducting scientific research into schizophrenia
• Support scientific exchange using the latest communications technology
• Function as a think tank for generating new ideas, techniques, and areas of investigation for schizophrenia research
• Develop quality control procedures, training manuals, and disseminate applicable information to clinicians and affiliated researchers state wide
• Recruit New South Wales neuroscientists and clinicians into schizophrenia research

Sign the Guestbook

View the Guestbook